Clinical Trials Directory

Trials / Completed

CompletedNCT04990310

Single Dose Absorption, Distribution, Metabolism, and Excretion Study of [14C]-CORT113176 in Healthy Male Participants

An Open Label, Single-dose, Single-period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-CORT113176 in Healthy Male Subjects

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
6 (actual)
Sponsor
Corcept Therapeutics · Industry
Sex
Male
Age
30 Years – 65 Years
Healthy volunteers
Accepted

Summary

This study will evaluate the mass balance recovery and metabolite profile, and will identify metabolite structures following a single oral dose of \[14C\]-CORT113176 in healthy male participants.

Conditions

Interventions

TypeNameDescription
DRUG[14C]-CORT113176\[14C\]-CORT113176 450 mg lipid formulation capsule for oral administration containing not more than 3.37 megaBequerel 14C.

Timeline

Start date
2021-08-18
Primary completion
2021-09-20
Completion
2021-09-20
First posted
2021-08-04
Last updated
2021-11-24

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT04990310. Inclusion in this directory is not an endorsement.